Thyrocare Technologies Ltd
NSE:THYROCARE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zhejiang TongLi Transmission Technology Co Ltd
SZSE:301255
|
CN |
ROCE
Return on Capital Employed (ROCE) measures how efficiently a company uses its capital to generate profit. It shows how much net income is earned for each dollar of capital employed.
Return on Capital Employed (ROCE) measures how efficiently a company uses its capital to generate profit. It shows how much net income is earned for each dollar of capital employed.
Peer Comparison
| Country | Company | Market Cap | ROCE | ||
|---|---|---|---|---|---|
| IN |
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
62.7B INR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
98.2B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
68.3B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
73.4B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
25.1B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.8B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.2B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.5B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.1B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.8B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.1B USD |
Loading...
|
Market Distribution
| Min | -2 275.6% |
| 30th Percentile | 2.6% |
| Median | 8.7% |
| 70th Percentile | 15.3% |
| Max | 5 652.3% |
Other Profitability Ratios
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
ROCE is calculated by dividing the EBIT by the Avg Capital Employed.
The current ROCE for Thyrocare Technologies Ltd is 35.1%, which is above its 3-year median of 21.4%.
Over the last 3 years, Thyrocare Technologies Ltd’s ROCE has increased from 18.1% to 35.1%. During this period, it reached a low of 14.3% on Jun 30, 2023 and a high of 35.1% on Jan 1, 2026.
